A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Completed · Phase 1

Conditions studied: Myelofibrosis

In brief

The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Key facts

Study ID

NCT00631462

Run by

TargeGen

People needed

59

Starts

2008-01-01

Expected to finish

2009-10-01

Last updated by the study team

2009-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia)
• At least 18 years of age.
• ECOG PS 0, 1, or 2.

You may not qualify if…

• Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
• Major surgery or radiation therapy within 28 days prior to initiation of study drug.

Where it is running

• UCSD Moores Cancer Center — San Diego, California, United States
• Stanford Comprehensive Cancer Center — Stanford, California, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Mayo Clinic, Rochester — Rochester, Minnesota, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.